LETROZOLE TEVA
 |
|
|
Package:
TABLETS: 30.
Dosage:
Adults/elderly: The recommended dose is 2.5 mg 1 x daily. In the adjuvant and extended adjuvant setting, treatment should continue for 5 years or until tumor relapse occurs, whichever comes first. In patients with metastatic disease, treatment should continue until tumour progression is evident. No dose adjustment is required for elderly patients.
Prescribing Restrictions:
Indications:
First-line treatment in postmenopausal women with hormone receptor positive, or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer.
Treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy.
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Contra-Indications:
Known hypersensitivity to the active ingredient, to other drugs belonging to the aromatase inhibitors group, or to any other ingredient of the preparation. Premenopausal endocrine status. Pregnancy and lactation. Severe hepatic disease.
Special Precautions:
Contact distributing company for full details.
Side Effects:
Contact distributing company for full details.
Drug Interactions:
